

Chemotherapy

Supplement issue No. 1 has its own Subject Index

- Absorption, intravesically administered
paclitaxel 311
- Adjuvant chemotherapy, stage IV
pancreatic cancer 305
- AIDS 21
- Alprazolam, nausea/vomiting control
280
- Alzheimer's disease 223
- Ambulatory infusion, ifosfamide 142
- Amifostine 200
- Ampicillin 64
- Ampicillin/sulbactam vs. cefazolin, cost-
effectiveness comparison 384
- Amyloid precursor protein 223
- Anaerobic bacteria, fluoroquinolone
resistance 256
- Angiogenesis, bladder tumors 291
- Anthracycline 280
- Antiangiogenic therapy, bladder tumors
291
- Antibacterial activity, 4th-generation
cephalosporins 80
- Antibiotic cross-resistance 80
– resistance 162, 177
– sensitivity testing 366
- Antifolate drugs 377
- Antifungals 21
- Anti-infectives 197, 243
- Antimicrobial combinations 387
– resistance 9
– susceptibility 182
- Antioxidant enzymes 57
- Antiretroviral therapy, *Cryptosporidium*
infection 193
- Aortic stop-flow technique, advanced
pancreatic carcinoma 1
- Apoptosis 93, 217, 272, 332
– proteins, inhibitor 272
- Arsenic 234
- Atoxyl 234
- ATS guidelines (American Thoracic
Society), pneumonia/sepsis treatment
227
- AVE8062 combretastatin A-4 derivative
357
- Bacteremia 147
- Bacterial attachment, DePuy Enduron®
orthopedic implant 286
- Béchamp, Antoine 234
- Biliary fistula 366
- Biofilm formation, *Pseudomonas*
aeruginosa 361
- Bladder cancer 291, 311
- Blood-brain barrier, pathological opening
223
- Borderline methicillin resistance 300
- Brain ischemia 223
- Breast cancer 57, 126, 280
- Brucellosis 352
–, chronic 27
- Camptothecin 32
- Cancer, cytotoxic drug treatment 336
- Candida parapsilosis* 252
- Carbapenems 70, 324
- Carboplatin 111
- Cefazolin vs. ampicillin/sulbactam, cost-
effectiveness comparison 384
- Cefepime 80
- Cefpirome 80
- Ceftizoxime 51
- Cell survival, clarithromycin 206
- Cephalosporins 268
- Cerebrospinal fluid, cytokines 363
– –, fluconazole pharmacokinetics 370
- Chronic lymphocytic leukemia 247
- Chronotherapy, systemic, metastatic
colorectal cancer 111
- Ciprofloxacin 352
- Cisplatin 103, 120, 154
- Cladribine (2-CdA) 247
- Clostridium hathewayi* 256
- Colorectal cancer 32, 111
- Combination chemotherapy 32, 111, 154,
247, 384
- Combretastatin A-4 357
- Community-acquired pneumonia 186,
227
- Compliance, anti-infectives 243
- Continuous infusion, cisplatin 120
– renal replacement therapy 211
– veno-venous hemofiltration 211
- Cryptosporidiosis 193
- Cyanidin-3-O- β -glucopyranoside 332
- Cycloguanil 377
- Cytodifferentiation, HL-60 leukemia cell
line 332
- Cytokine gene expression, peritoneal
cavity 15
- Cytokines, cerebrospinal fluid 363
- Cytotoxic drugs, intestinal permeability
336
- Daptomycin 64
- Degranulation 206
- 4,9-Diazapyrenium derivatives 217
- Docetaxel 120
- Doxifluridine 32
- Doxorubicin 132
- Doxycycline 27
- Drug delivery systems 311
– interactions, anti-infectives 197
– penetration, *Streptococcus pneumoniae*
infection 339
- Efflux pump 40, 256
- Ehrlich, Paul 234
- Endotoxin 324
- Eosinophils, clarithromycin treatment
effects 206
- Epithelial lining fluid 339
- Eradication, *Helicobacter pylori* 243
- E test, *Porphyromonas/Prevotella* species
9
- Etoposide 247
- Exotoxin A 324
- Extracellular enzyme production 21
- Family physicians, sore throat
management 381
- Farnesyl transferase inhibitor L-744, 832
319
- Fatty acids 57
- Fluconazole 370
- Fluoroquinolone resistance 256
- Fluoroquinolones 40, 70, 256
- 5-Fluorouracil 93, 103, 132, 319
- 5-Fluorouracil/leucovorin 111
- Fosfomycin 162
- Fractional inhibitory concentration index
387
- Gastric cancer 15, 384
- Gemcitabine 305
- Glucocorticoids 116
- Glycocalyx 361
- Gram-positive bacteria 263
– uropathogens 64
- Granisetron 280
- GyrA mutation 70
- GyrB mutation 70
- Helicobacter pylori* eradication 243
- Hepatic artery infusion, metastatic
colorectal cancer 111
- Hepatitis C 167
- Histone H1 57
- HIV 21
- HL-60 cells 332
- Hospital-acquired pneumonia 227
- HT-29 human colon carcinoma cells 93

Downloaded from <http://karger.com/che/article-pdf/51/6/395/2397018/000089499.pdf> by guest on 24 September 2023

- Hyaluronan 132
Hydrocephalus 370
Hypersensitivity reactions, paclitaxel 116
Hypopharyngeal carcinoma cell line PNUH-12 103
- IB-MECA A₃ adenosine receptor agonist 272
Ifosfamide 142
Immunocompromised patients, cryptosporidiosis treatment 193
Intestinal permeability, cytotoxic agents 336
Intraoperative fluid balance, ceftizoxime tissue diffusion 51
Intraperitoneal chemotherapy, gastric cancer 15
In vitro activity, ciprofloxacin 40
Irinotecan (CPT-11) 93, 111
Irinotecan (CPT-11)/5-FU combination 93
Isoniazid 76
- Jurkat cells 332
- Ketolides 339
- β-Lactam antibiotics 80
β-Lactamase 300
Levamisole 27
Levofloxacin 40
Linezolid 64, 86
Lymphocyte subgroup ratios, chronic brucellosis 27
- Macrolides 268
Macrophages, telithromycin lung penetration 339
Malignancy, hematological 147
Mast cells, clarithromycin treatment effects 206
Meropenem 211
Mesna 142
Methicillinase 300
Methicillin-resistant *Staphylococcus aureus* 363, 387
Minocycline 291
Mitomycin C 1
Mn-SOD activity 93
M-typing, *Streptococcus pyogenes* 268
Multidrug resistance, HL-60 leukemia cells 272
Mupirocin 361
- Mycobacterium tuberculosis* mutant prevention concentrations, isoniazid/rifabutin/rifampicin 76
- Nausea control, alprazolam 280
Neisseria gonorrhoeae 89
Neutrophils, clarithromycin treatment effects 206
Non-Hodgkin's lymphoma 247
Non-small-cell lung cancer 120
Nosocomial infections 177
– pathogens 40
- OprD production 70
Orthopedic surgery, infections 286
Ovarian cancer 347
Oxidative stress 57
- Paclitaxel 116, 126, 200, 311
–, intravesical administration 311
Pancreatic cancer 1, 305
Panipenem 387
ParC mutation 70
PEG guidelines (Paul Ehrlich Society of Chemotherapy), pneumonia/sepsis treatment 227
Peginterferon alpha-2b 167
Peptidoglycan 324
Percutaneous drainage, pyogenic liver abscess 366
Peritoneal seeding, gastric cancer cells 15
– washings 15
Phagocytic function, chronic brucellosis patients 27
Pharyngitis 381
Phenazines 263
Plasmodium falciparum clones 377
Platinum-resistant epithelial ovarian cancer 347
Pneumococci 186
PNU153429 distamycin A derivative 291
Polyethylene implant, bacterial attachment 286
Porphyromonas species 9
Posttraumatic liver abscess 366
Prevotella species 9
Prophylactic antibiotic therapy, gastrectomy patients 384
Prostheses, bacterial attachment 286
Protease inhibitors 193
Proteinase inhibitors 252
Pseudomonas aeruginosa 324, 361, 387
- Psoriasis 167
Purine nucleoside analogues 247
Pyogenic liver abscess 366
Pyrimethamine 377
- Radiation resistance, colon cancer cell line DLD-1 319
Regional chemotherapy, advanced pancreatic carcinoma 1
Resistant subpopulations, *Staphylococcus aureus* 86
Respiratory tract pathogens 182
Ribavirin 167
Rifabutin 76
Rifampicin 27, 76
Riminothienopyridines 263
- Salmonella* mutants 40
Salvarsan 234
Secreted aspartyl proteinases 252
Sepsis 227
Sleeping sickness 234
Sore throat 381
Stage IV pancreatic cancer 305
Staphylococcus aureus 86, 300
Streptococcus pyogenes 268
Superoxide release 206
Surgical drainage, pyogenic liver abscess 366
– infection prophylaxis 51
Syphilis 234
- Taxanes 116
Tecogalan 291
Telithromycin 182, 186, 268, 339
Tetramethylpiperidine 263
TNP-470 fumagillin derivative 291
Tonsillitis 381
Topoisomerase-II 217
Topotecan 154, 347
Trichophyton rubrum 21
Trypanosomes 234
Tumor blood flow 357
- Ureaplasma urealyticum* 89
Urethritis 89
Urinary pathogens 162
– tract infection, uncomplicated 162
- Vancomycin 64, 363
–, intraventricular 363
Vomiting control, alprazolam 280